Developer docs
API playgroundTry for free, no card

Search company profiles

Brandon BioCatalyst

Full company profile

uuid000rg2j

Namestring
Brandon BioCatalyst
Legal namestring
Brandon BioCatalyst
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, structured as a multi-stakeholder collaboration vehicle that connects more than 50 leading medical research institutes and hospitals across the region with institutional capital from five major Australian superannuation funds, CSL (Australia's largest biopharmaceutical company), and federal and state governments in both countries. Founded in 2007 as the Medical Research Commercialisation Fund (MRCF) and rebranded to its current name in March 2022, the organisation is managed by Brandon Capital Partners and targets the "first Valley of Death" gap in commercialising Australasian biomedical discoveries. It provides both venture capital and operational company-building support, rather than acting solely as a passive investor.

The platform operates multiple successive VC funds (at least six vehicles from BB1 in 2007 to BB6 in 2024), the CUREator national biotechnology incubator (established 2021 with $40 million MRFF backing, providing up to $5M per project in non-dilutive funding), the CUREator BioMedTech Incubator (delivered in partnership with CSIRO from March 2023 with $50M in federal funding), and the CUREator+ Dementia and Cognitive Decline Incubator (August 2023 / February 2024, $50M with ANDHealth). It also runs capability-building programs including the Biotech Innovators Program, the Brandon BioCatalyst Internship, Women in Leadership Development (WILD), and Cicada x Brandon BioCatalyst at Westmead. Returns are generated through portfolio company exits, with three landmark validation exits — Fibrotech Therapeutics to Shire for US$557M in 2014, Spinifex Pharmaceuticals to Novartis for US$725M in 2015, and Elastagen to Allergan for US$95M in 2018 — alongside an active portfolio spanning oncology, neuroscience, infectious disease, metabolic disease, pain, allergy, ADCs, CAR-T, mitochondrial therapeutics, and medtech.

The business model is fund-management economics: management fees on committed/called capital across successive BB funds, plus carried interest on exits, augmented by federal government grants underwriting CUREator operations. Brandon Capital serves as GP/manager. Customers split into LPs (concentrated super funds, CSL, and government programs) on the capital side and portfolio companies (50+ startups spun out of member institutes and increasingly co-led internationally) on the deployment side. Deal sourcing flows through member research institutes and direct outreach to researchers and clinicians, supplemented by CUREator's national roadshow across Adelaide, Brisbane, Melbourne, Sydney, and Perth.

Short descriptiontext

Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, connecting 50+ medical research institutes with five superannuation funds, CSL, and government capital to commercialize early-stage biomedical discoveries through successive VC funds and the CUREator incubator.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical venture capital, biotech incubator funding, medical research commercialization, life science seed investment, pharma MedTech deal flow
Industry1 code
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Investment Advice6282
Product category
Life Science Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeAffiliate Referral
Description

Brandon BioCatalyst generates returns through successful exits of portfolio companies. Notable exits include Fibrotech Therapeutics (US$557M to Shire in 2014), Spinifex Pharmaceuticals (US$725M to Novartis in 2015), and Elastagen (US$95M to Allergan in 2018). The fund manages multiple Brandon BioCatalyst Funds with investments from superannuation funds seeking long-term returns.

brandonbiocatalyst.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1CUREator
Description

Australian national biotechnology incubator supporting the development of pre-clinical and clinical stage medical innovation, funded by the Australian Government's Medical Research Future Fund.

brandonbiocatalyst.com
+2 more records
Core offering1 text field

Brandon BioCatalyst is a life-science investment collaboration platform that deploys pooled institutional capital into early-stage biomedical companies spun out from member research organizations, while also operating the CUREator national biotech incubator (including BioMedTech and Dementia & Cognitive Decline streams) which provides non-dilutive grant funding and commercialization support. It supplements capital with entrepreneur training programs (Biotech Innovators Program, Internship, WILD, Cicada at Westmead, Queensland TACSGP) and partners with CSL and more than 50 medical research institutes, universities, and hospitals across Australia and New Zealand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Fibrotech Therapeutics sold to Shire for US$557 million (July 2014)
+3 more records
Product overview1 text field

Brandon BioCatalyst is a life science investment fund and collaboration platform comprising multiple programs. It operates CUREator, Australia's national biotechnology incubator providing up to $5 million per project in non-dilutive funding along with commercial guidance and mentorship. The organization also runs multiple training programs including the Biotech Innovators Program, Brandon BioCatalyst Internship, and Women in Leadership Development (WILD). Investment activities are managed by Brandon Capital, supporting early-stage biomedical discoveries from member research organizations through venture capital funds. The portfolio includes companies across therapeutics, medical devices, and health technology sectors.

Product and service1 record
1Brandon BioCatalyst Investment Fund
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

More than 50 leading medical research institutes and hospitals across Australia and New Zealand as part of the Brandon BioCatalyst network. Includes The Centenary Institute, Florey Institute of Neuroscience and Mental Health, and others.

2Peter MacCallum Cancer Centre
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Currus Biologics was spun out of Peter MacCallum Cancer Centre based on research from leading immunotherapy scientists Mike Kershaw and Clare Slaney.

brandonbiocatalyst.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Kraken Coding expanded internationally through partnership with Northwest Telapharmacy in Canada, supporting four hospitals across multiple sites.

4CSIRO
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CUREator, in partnership with Australia's national science agency CSIRO, delivers a national BioMedTech Incubator program to accelerate early-stage therapeutics development. CSIRO provides Biomedical Manufacturing subject matter experts.

brandonbiocatalyst.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Brandon BioCatalyst, in partnership with ANDHealth, was selected by the Federal Government to deliver the $50m Dementia and Cognitive Decline Incubator and BioMedTech Incubator Program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ANDHealth is Australia's leading digital health commercialisation fund and accelerator. It is comparable because Brandon BioCatalyst partners directly with ANDHealth to deliver the Federal Government's $50m Dementia and Cognitive Decline Incubator and BioMedTech Incubator Programs, and both target AU/NZ research translation.

TypeBroad incumbent
Description

OrbiMed is one of the world's largest healthcare-dedicated investment firms spanning venture, growth, and public equities. It is a broad incumbent peer because it invests across the same therapeutic, medical device, and biopharma categories that Brandon BioCatalyst targets, but at global scale.

TypeBroad incumbent
Description

ARCH Venture Partners is a US-based premier early-stage technology and life science venture firm that partners with universities and research institutes to commercialise breakthrough science. It is a broad incumbent peer because it pioneered the same university/research-institute-sourced biotech investment model at much larger scale.

4Uniseed
TypeDirect peer
Description

Uniseed is Australia's longest-running commercialisation-focused venture fund, jointly backed by leading Australian universities to commercialise early-stage research. It is a direct peer because it operates an identical early-stage biomedical commercialisation model sourced from Australian research institutes, and frequently co-invests with Brandon BioCatalyst (e.g., AU$11.5M Currus Biologics Series A).

TypeDirect peer
Description

Main Sequence Ventures is Australia's deep-tech and science commercialisation VC fund managing the CSIRO Innovation Fund. It is comparable because it invests in Australian research-sourced life science and biotech opportunities from early stages through to growth, often co-investing with Brandon BioCatalyst (e.g., into Currus Biologics).

TypeBroad incumbent
Description

Forbion is a leading European life sciences venture capital firm focused on developing new drugs and technologies. It is a broad incumbent peer because it pursues a similar active build-and-operate model in early-stage therapeutics with comparable investor structures.

TypeBroad incumbent
Description

Advent Life Sciences is a UK-based venture capital firm investing in early- and mid-stage life sciences companies. It is a broad incumbent peer because it runs a comparable research-sourced, therapeutics-focused venture model to Brandon BioCatalyst but operates primarily across European biotech.

TypeBroad incumbent
Description

Atlas Venture is a leading global biotech-focused venture capital firm building and operating biotech companies from inception. It is a broad incumbent peer because it pursues the same 'company creation + active operation' model at much larger scale and AUM, serving as the international benchmark for Brandon BioCatalyst's model.

TypeDirect peer
Description

BioGeneration Ventures (BGV) is a European venture capital firm focused on early-stage life sciences companies spun out from universities and research institutes. It is a direct peer because it executes the same dedicated research-institute-sourced early-stage biotech venture model as Brandon BioCatalyst, including active company-building and co-investment with strategic partners.

TypeBroad incumbent
Description

Sofinnova Partners is a leading European life sciences venture capital firm investing from seed to late-stage across therapeutics and medtech. It is a broad incumbent peer because it operates the same active early-stage life sciences model as Brandon BioCatalyst and has supported comparable European biotech exits.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment9 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brandon BioCatalyst

Life Science Venture Capitalbrandonbiocatalyst.com

Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, connecting 50+ medical research institutes with five superannuation funds, CSL, and government capital to commercialize early-stage biomedical discoveries through successive VC funds and the CUREator incubator.

What Brandon BioCatalyst does

Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, structured as a multi-stakeholder collaboration vehicle that connects more than 50 leading medical research institutes and hospitals across the region with institutional capital from five major Australian superannuation funds, CSL (Australia's largest biopharmaceutical company), and federal and state governments in both countries. Founded in 2007 as the Medical Research Commercialisation Fund (MRCF) and rebranded to its current name in March 2022, the organisation is managed by Brandon Capital Partners and targets the "first Valley of Death" gap in commercialising Australasian biomedical discoveries. It provides both venture capital and operational company-building support, rather than acting solely as a passive investor.

The platform operates multiple successive VC funds (at least six vehicles from BB1 in 2007 to BB6 in 2024), the CUREator national biotechnology incubator (established 2021 with $40 million MRFF backing, providing up to $5M per project in non-dilutive funding), the CUREator BioMedTech Incubator (delivered in partnership with CSIRO from March 2023 with $50M in federal funding), and the CUREator+ Dementia and Cognitive Decline Incubator (August 2023 / February 2024, $50M with ANDHealth). It also runs capability-building programs including the Biotech Innovators Program, the Brandon BioCatalyst Internship, Women in Leadership Development (WILD), and Cicada x Brandon BioCatalyst at Westmead. Returns are generated through portfolio company exits, with three landmark validation exits — Fibrotech Therapeutics to Shire for US$557M in 2014, Spinifex Pharmaceuticals to Novartis for US$725M in 2015, and Elastagen to Allergan for US$95M in 2018 — alongside an active portfolio spanning oncology, neuroscience, infectious disease, metabolic disease, pain, allergy, ADCs, CAR-T, mitochondrial therapeutics, and medtech.

The business model is fund-management economics: management fees on committed/called capital across successive BB funds, plus carried interest on exits, augmented by federal government grants underwriting CUREator operations. Brandon Capital serves as GP/manager. Customers split into LPs (concentrated super funds, CSL, and government programs) on the capital side and portfolio companies (50+ startups spun out of member institutes and increasingly co-led internationally) on the deployment side. Deal sourcing flows through member research institutes and direct outreach to researchers and clinicians, supplemented by CUREator's national roadshow across Adelaide, Brisbane, Melbourne, Sydney, and Perth.

Brandon BioCatalyst firmographics

Firmographics
Name
Brandon BioCatalyst
Legal name
Brandon BioCatalyst
Website
https://brandonbiocatalyst.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, connecting 50+ medical research institutes with five superannuation funds, CSL, and government capital to commercialize early-stage biomedical discoveries through successive VC funds and the CUREator incubator.
Ownership category
akta.pro rank

Brandon BioCatalyst industry classification

Industry
Product category
Life Science Venture Capital
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Biomedical venture capital
  • Biotech incubator funding
  • Medical research commercialization
  • Life science seed investment
  • Pharma MedTech deal flow

Where Brandon BioCatalyst is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Brandon BioCatalyst business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Returns: Brandon BioCatalyst generates returns through successful exits of portfolio companies. Notable exits include Fibrotech Therapeutics (US$557M to Shire in 2014), Spinifex Pharmaceuticals (US$725M to Novartis in 2015), and Elastagen (US$95M to Allergan in 2018). The fund manages multiple Brandon BioCatalyst Funds with investments from superannuation funds seeking long-term returns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Brandon BioCatalyst product offering

Product offering

Core offering

Brandon BioCatalyst is a life-science investment collaboration platform that deploys pooled institutional capital into early-stage biomedical companies spun out from member research organizations, while also operating the CUREator national biotech incubator (including BioMedTech and Dementia & Cognitive Decline streams) which provides non-dilutive grant funding and commercialization support. It supplements capital with entrepreneur training programs (Biotech Innovators Program, Internship, WILD, Cicada at Westmead, Queensland TACSGP) and partners with CSL and more than 50 medical research institutes, universities, and hospitals across Australia and New Zealand.

Product overview

Brandon BioCatalyst is a life science investment fund and collaboration platform comprising multiple programs. It operates CUREator, Australia's national biotechnology incubator providing up to $5 million per project in non-dilutive funding along with commercial guidance and mentorship. The organization also runs multiple training programs including the Biotech Innovators Program, Brandon BioCatalyst Internship, and Women in Leadership Development (WILD). Investment activities are managed by Brandon Capital, supporting early-stage biomedical discoveries from member research organizations through venture capital funds. The portfolio includes companies across therapeutics, medical devices, and health technology sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • CUREator: Australian national biotechnology incubator supporting the development of pre-clinical and clinical stage medical innovation, funded by the Australian Government's Medical Research Future Fund.
  • CUREator BioMedTech Incubator
  • CUREator+

Products and services

  • Brandon BioCatalyst Investment Fund

Quantifiable outcome

  • Fibrotech Therapeutics sold to Shire for US$557 million (July 2014)
  • +3 more outcomes

Companies that use Brandon BioCatalyst

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Brandon BioCatalyst technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Brandon BioCatalyst partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Medical Research Institutes NetworkcoreStrategic or Co-development PartnerMore than 50 leading medical research institutes and hospitals across Australia and New Zealand as part of the Brandon BioCatalyst network. Includes The Centenary Institute, Florey Institute of Neuroscience and Mental Health, and others.
  • Peter MacCallum Cancer CentrecoreStrategic or Co-development PartnerCurrus Biologics was spun out of Peter MacCallum Cancer Centre based on research from leading immunotherapy scientists Mike Kershaw and Clare Slaney.
  • Northwest TelepharmacyminorStrategic or Co-development PartnerKraken Coding expanded internationally through partnership with Northwest Telapharmacy in Canada, supporting four hospitals across multiple sites.
  • CSIROcoreStrategic or Co-development PartnerCUREator, in partnership with Australia's national science agency CSIRO, delivers a national BioMedTech Incubator program to accelerate early-stage therapeutics development. CSIRO provides Biomedical Manufacturing subject matter experts.
  • ANDHealthcoreStrategic or Co-development PartnerBrandon BioCatalyst, in partnership with ANDHealth, was selected by the Federal Government to deliver the $50m Dementia and Cognitive Decline Incubator and BioMedTech Incubator Program.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Brandon BioCatalyst competitors and assessment

Company assessment

Direct peers

  • ANDHealth: ANDHealth is Australia's leading digital health commercialisation fund and accelerator. It is comparable because Brandon BioCatalyst partners directly with ANDHealth to deliver the Federal Government's $50m Dementia and Cognitive Decline Incubator and BioMedTech Incubator Programs, and both target AU/NZ research translation.
  • Uniseed: Uniseed is Australia's longest-running commercialisation-focused venture fund, jointly backed by leading Australian universities to commercialise early-stage research. It is a direct peer because it operates an identical early-stage biomedical commercialisation model sourced from Australian research institutes, and frequently co-invests with Brandon BioCatalyst (e.g., AU$11.5M Currus Biologics Series A).
  • Main Sequence Ventures: Main Sequence Ventures is Australia's deep-tech and science commercialisation VC fund managing the CSIRO Innovation Fund. It is comparable because it invests in Australian research-sourced life science and biotech opportunities from early stages through to growth, often co-investing with Brandon BioCatalyst (e.g., into Currus Biologics).
  • BioGeneration Ventures: BioGeneration Ventures (BGV) is a European venture capital firm focused on early-stage life sciences companies spun out from universities and research institutes. It is a direct peer because it executes the same dedicated research-institute-sourced early-stage biotech venture model as Brandon BioCatalyst, including active company-building and co-investment with strategic partners.

Broad incumbents

  • OrbiMed: OrbiMed is one of the world's largest healthcare-dedicated investment firms spanning venture, growth, and public equities. It is a broad incumbent peer because it invests across the same therapeutic, medical device, and biopharma categories that Brandon BioCatalyst targets, but at global scale.
  • ARCH Venture Partners: ARCH Venture Partners is a US-based premier early-stage technology and life science venture firm that partners with universities and research institutes to commercialise breakthrough science. It is a broad incumbent peer because it pioneered the same university/research-institute-sourced biotech investment model at much larger scale.
  • Forbion: Forbion is a leading European life sciences venture capital firm focused on developing new drugs and technologies. It is a broad incumbent peer because it pursues a similar active build-and-operate model in early-stage therapeutics with comparable investor structures.
  • Advent Life Sciences: Advent Life Sciences is a UK-based venture capital firm investing in early- and mid-stage life sciences companies. It is a broad incumbent peer because it runs a comparable research-sourced, therapeutics-focused venture model to Brandon BioCatalyst but operates primarily across European biotech.
  • Atlas Venture: Atlas Venture is a leading global biotech-focused venture capital firm building and operating biotech companies from inception. It is a broad incumbent peer because it pursues the same 'company creation + active operation' model at much larger scale and AUM, serving as the international benchmark for Brandon BioCatalyst's model.
  • Sofinnova Partners: Sofinnova Partners is a leading European life sciences venture capital firm investing from seed to late-stage across therapeutics and medtech. It is a broad incumbent peer because it operates the same active early-stage life sciences model as Brandon BioCatalyst and has supported comparable European biotech exits.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Brandon BioCatalyst social profiles

Digital presence

Brandon BioCatalyst financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brandon BioCatalyst leadership team

Management profile

Number of profiles

Profiles4 records

Brandon BioCatalyst funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brandon BioCatalyst M&A and investment

M&A and investment

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brandon BioCatalyst

What does Brandon BioCatalyst do?

Brandon BioCatalyst is a life-science investment collaboration platform that deploys pooled institutional capital into early-stage biomedical companies spun out from member research organizations, while also operating the CUREator national biotech incubator (including BioMedTech and Dementia & Cognitive Decline streams) which provides non-dilutive grant funding and commercialization support. It supplements capital with entrepreneur training programs (Biotech Innovators Program, Internship, WILD, Cicada at Westmead, Queensland TACSGP) and partners with CSL and more than 50 medical research institutes, universities, and hospitals across Australia and New Zealand.

Is Brandon BioCatalyst a public or private company?

Brandon BioCatalyst is a private company. It is classified as venture growth investor backed and is currently operating.

When was Brandon BioCatalyst founded?

Brandon BioCatalyst was founded in 2007. It employs 11 to 50 people.

Where is Brandon BioCatalyst based?

Brandon BioCatalyst is headquartered in Melbourne, Australia, in the Oceania region.

How does Brandon BioCatalyst make money?

One revenue line is on record: investment Returns.

Who are Brandon BioCatalyst's main competitors?

Direct peers on record are ANDHealth, Uniseed, Main Sequence Ventures and BioGeneration Ventures. Broad incumbents are OrbiMed, ARCH Venture Partners, Forbion, Advent Life Sciences, Atlas Venture and Sofinnova Partners.

Does Brandon BioCatalyst have an API?

No public API is recorded for Brandon BioCatalyst.

What industry is Brandon BioCatalyst in?

Brandon BioCatalyst's product category is Life Science Venture Capital. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 54169 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Biotech DispatchCUREator+ backs six Australian startups with $13.5 million to advance new health technologiesSix Australian health and medical technology startups have secured a combined $13.5 million in milestone-based funding through the second round of the CUREator+ commercialisation program. Delivered by Brandon BioCatalyst and ANDHealth with support from the Australian Government’s Medical Research Future Fund, the initiative aims to advance therapies and digital health tools for conditions including cancer, inflammatory diseases, and cardiovascular disorders. The largest allocations went to Aleris Therapeutics, Frontier Inflammasome Therapeutics, and Luma Bio, each receiving $2.5 million to progress their respective technologies toward clinical adoption and global market entry.BrandonbiocatalystBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding. – Brandon BioCatalystCUREator, Australia's national biotech incubator managed by Brandon BioCatalyst, announced $1.865 million in top-up funding for four companies across their Preclinical and Health Security streams. Alkira Bio, Myostellar, and GILZRx will receive $1.365 million from the Federal Government's Medical Research Future Fund ESTAC grant, while Cytophenix will receive $500,000 through the Health Security stream to advance its AI-powered antimicrobial susceptibility testing platform FloCAST. The funding recognizes each recipient's substantial progress toward commercialization, with multiple companies reporting secured private capital and commercial partnerships since receiving initial CUREator grants.Health$100 million to support Australian medical innovationsThe Albanese Government awarded nearly $100 million in funding to Brandon BioCatalyst, ANDHealth Pty Ltd, and Biointelect Pty Ltd to support emerging Australian biomedical and medical technology innovations. These selected companies will act as incubators to help commercialize medical products for small and medium-sized enterprises under the Medical Research Future Fund’s initiative.PerkinsFederal funding helps WA Biotech firm save livesWestern Australian biotech startup Cytophenix has been awarded a $500,000 grant from the Brandon BioCatalyst’s CUREator Incubator to accelerate its go-to-market strategy for FloCAST, an AI-powered diagnostic platform. The technology is designed to identify effective antibiotics for life-threatening infections within four hours, significantly reducing patient mortality and combating global antibiotic resistance. This funding builds upon an initial grant received last year and supports collaborations with the Harry Perkins Institute of Medical Research and The University of Western Australia.BrandonbiocatalystFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential – Brandon BioCatalystCUREator by Brandon BioCatalyst has deployed $7.21 million in funding to eight biotech companies across clinical and preclinical streams through the Medical Research Future Fund’s ESTAC grant program. The allocation includes $5.84 million for five clinical-stage firms, such as GPN Vaccines and Ena Respiratory, to advance novel drug efficacy trials, alongside $1.37 million in top-up grants for three preclinical projects including Currus Biologics. This deployment reinforces CUREator's role in leveraging public funds to drive private sector investment and accelerate the commercialization of Australian biomedical innovations.RespirionpharmaRespirion Selected For Early-Stage Translation and Commercialisation Support (ESTAC) grant. - Respirion PharmaCUREator by Brandon BioCatalyst has deployed $7.21 million in funding to eight biotech companies through the Federal Government’s Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) grant. Respirion Pharmaceuticals was selected as one of five clinical-stage recipients, receiving a portion of the $5.84 million allocated to that stream to explore novel drug efficacies.Dynamic BusinessCUREator+ delivers $50m funding boost for BioMedTech startupsCUREator+ is a $50 million fund administered by Brandon BioCatalyst and ANDHealth, offering Australian health startups up to $5 million in non-dilutive funding. The program, endorsed by the Medical Research Future Fund, disburses funding in tranches tied to commercial milestones. Applications are now open.BrandoncapitalAustralia’s first national biotech incubator announces round one funding to support life science breakthroughsCUREator, Australia’s national biotech incubator managed by Brandon BioCatalyst, has awarded $17.4 million in funding to 23 projects targeting global health concerns such as diabetes, cardiovascular disease, and cancer. The funding supports the development of Australian biotech innovations through two streams: pre-clinical proof-of-concept and clinical-stage drug therapies, with recipients including Phrenix Therapeutics and Liperate.VenturesUQ research recognised in national biomedical incubatorUniQuest secured $3 million in funding for four University of Queensland biomedical startups through the Medical Research Future Fund's CUREator Scheme. This investment supports early-stage research aimed at developing treatments for cancer, inflammatory diseases, and type 1 diabetes. The scheme is managed by Brandon BioCatalyst to help progress preclinical programs to advanced proof-of-concept stages.